

# Publikationsliste

## 1. Originalarbeiten

1. Häfliger J, Schwarzfischer M, Atrott K, Stanzel C, Morsy Y, Wawrzyniak M, Lang S, Valenta T, Basler K, Rogler G, **Scharl M**, Spalinger MR.  
*Glycoprotein (GP)96 Is Essential for Maintaining Intestinal Epithelial Architecture by Supporting Its Self-Renewal Capacity.*  
Cell Mol Gastroenterol Hepatol. 2022 Dec 11:S2352-345X(22)00252-1. doi: 10.1016/j.jcmgh.2022.12.004. Online ahead of print
2. Schwarzfischer M, Niechcial A, Handler K, Morsy Y, Wawrzyniak M, Laimbacher AS, Atrott K, Manzini R, Baebler K, Hering L, Katkeviciute E, Häfliger J, Lang S, Keller ME, Woodtli J, Eisenbeiss L, Kraemer T, Schraner EM, Wiesendanger M, Zeissig S, Rogler G, Moor AE, **Scharl M**, Spalinger MR.  
*TiO<sub>2</sub> nanoparticles abrogate the protective effect of the Crohn's disease-associated variation within the PTPN22 gene locus.*  
Gut. 2022 Oct 3:gutjnl-2021-325911. doi: 10.1136/gutjnl-2021-325911. Online ahead of print
3. Rostaher A, Morsy Y, Favrot C, Unterer S, Schnyder M, **Scharl M**, Fischer NM.  
*Comparison of the Gut Microbiome between Atopic and Healthy Dogs-Preliminary Data.*  
Animals (Basel). 2022 Sep 12;12(18):2377. doi: 10.3390/ani12182377.
4. Bianchi R, Mamadou-Pathé B, von Känel R, Roth R, Schreiner P, Rossel JB, Burk S, Dora B, Kloth P, Rickenbacher A, Turina M, Greuter T, Misselwitz B, **Scharl M**, Rogler G, Biedermann L; or the Swiss IBD cohort study.  
*Effect of closed and permanent stoma on disease course, psychological well-being and working capacity in Swiss IBD cohort study patients.*  
PLoS One. 2022 Sep 16;17(9):e0274665. doi: 10.1371/journal.pone.0274665. eCollection 2022.
5. Jordi SBU, Lang BM, Wyss J, Auschra B, Yilmaz B, Krupka N, Greuter T, Schreiner P, Biedermann L, Preisig M, von Känel R, Rogler G, Bégré S, Misselwitz B; **Swiss IBD cohort study group.**  
*The personality traits activity, self-reproach, and negative affect jointly predict clinical recurrence, depressive symptoms, and low quality of life in inflammatory bowel disease patients.*  
J Gastroenterol. 2022 Nov;57(11):848-866 doi: 10.1007/s00535-022-01902-7. Epub 2022 Jul 28
6. Gueguen E, Morsy Y, **Scharl M**, Krämer SD, Zaugg M, Hersberger M, Rogler G, Wawrzyniak M.  
*Endothelial Barrier Disruption by Lipid Emulsions Containing a High Amount of N3 Fatty Acids (Omegaven) but Not N6 Fatty Acids (Intralipid)*  
Cells. 2022 Jul 14;11(14):2202. doi: 10.3390/cells11142202
7. Schwarzfischer M, Niechcial A, Lee SS, Sinnet B, Wawrzyniak M, Laimbacher A, Atrott K, Manzini R, Morsy Y, Häfliger J, Lang S, Rogler G, Kaegi R, **Scharl M**, Spalinger MR  
*Ingested nano- and micro-sized polystyrene particles surpass the intestinal barrier and accumulate in the body.*  
NanolImpact. 2022 Jan;25:100374. doi: 10.1016/j.impact.2021.100374. Epub 2021 Dec 13

8. de Vallière C, Cosin-Roger J, Baebler K, Schoepflin A, Mamie C, Mollet M, Schuler C, Bengs S, Lang S, **Scharl M**, Seuwen K, Ruiz PA, Hausmann M, Rogler G.  
*pH-Sensing G Protein-Coupled Receptor OGR1 (GPR68) Expression and Activation Increases in Intestinal Inflammation and Fibrosis.*  
Int J Mol Sci. 2022 Jan 26;23(3):1419. doi: 10.3390/ijms23031419.
9. Busenhardt P, Montalban-Arques A, Katkeviciute E, Morsy Y, Van Passen C, Hering L, Atrott K, Lang S, Garzon JFG, Naschberger E, Hartmann A, Rogler G, Stürzl M, Spalinger MR, **Scharl M**.  
*Inhibition of integrin  $\alpha\beta6$  sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer.*  
J Immunother Cancer. 2022 Feb;10(2):e003465. doi: 10.1136/jitc-2021-003465.
10. Morsy Y, Brillant N, Franc Y, **Scharl M**, Wawrzyniak M, On Behalf Of The Swiss Ibd Cohort Study Group.  
*Unravelling the Impact of the Genetic Variant rs1042058 within the TPL2 Risk Gene Locus on Molecular and Clinical Disease Course Patients with Inflammatory Bowel Disease.*  
Cells. 2021 Dec 20;10(12):3589. doi: 10.3390/cells10123589
11. de Vallière C, Bähler K, Busenhardt P, Schwarzfischer M, Maeyashiki C, Schuler C, Atrott K, Lang S, Spalinger MR, **Scharl M**, Ruiz-Castro PA, Hausmann M, Rogler G.  
*A Novel OGR1 (GPR68) Inhibitor Attenuates Inflammation in Murine Models of Colitis.*  
Inflamm Intest Dis. 2021 Jul 19;6(3):140-153. doi: 10.1159/000517474. eCollection 2021 Sep.
12. Mamie C, Bruckner RS, Lang S, Shpigel NY, Turina M, Rickenbacher A, Cabalzar-Wondberg D, Chvatchko Y, Rogler G, **Scharl M**.  
*MMP9 expression in intestinal fistula from patients with fistulizing CD and from human xenograft mouse model.*  
Tissue Barriers . 2022 Apr 3;10(2):1994350. doi: 10.1080/21688370.2021.1994350. Epub 2021 Oct 28
13. Bittner ZA, Liu X, Mateo Tortola M, Tapia-Abellán A, Shankar S, Andreeva L, Mangan M, Spalinger M, Kalbacher H, Düwell P, Lovotti M, Bosch K, Dickhöfer S, Marcu A, Stevanović S, Herster F, Cardona Gloria Y, Chang TH, Bork F, Greve CL, Löffler MW, Wolz OO, Schilling NA, Kümmerle-Deschner JB, Wagner S, Delor A, Grimbacher B, Hantschel O, **Scharl M**, Wu H, Latz E, Weber ANR.  
*BTK operates a phospho-tyrosine switch to regulate NLRP3 inflammasome activity.*  
J Exp Med. 2021 Nov 1;218(11):e20201656. doi: 10.1084/jem.20201656. Epub 2021 Sep 23
14. Montalban-Arques A, Katkeviciute E, Busenhardt P, Bircher A, Wirbel J, Zeller G, Morsy Y, Borsig L, Glaus Garzon JF, Müller A, Arnold IC, Artola-Boran M, Krauthammer M, Sintsova A, Zamboni N, Leventhal GE, Berchtold L, de Wouters T, Rogler G, Baebler K, Schwarzfischer M, Hering L, Olivares-Rivas I, Atrott K, Gottier C, Lang S, Boyman O, Fritsch R, Manz MG, Spalinger MR, **Scharl M**.  
*Commensal Clostridiales strains mediate effective anti-cancer immune response against solid tumors.*  
Cell Host Microbe. 2021 Oct 13;29(10):1573-1588.e7. doi: 10.1016/j.chom.2021.08.001.
15. Denoth L, Juillerat P, Kremer AE, Rogler G, **Scharl M**, Yilmaz B, Bluemel S, On Behalf Of The Swiss Ibd Cohort Study.  
*Modulation of the Mucosa-Associated Microbiome Linked to the PTPN2 Risk Gene in Patients with Primary Sclerosing Cholangitis and Ulcerative Colitis.*  
Microorganisms. 2021 Aug 17;9(8):1752. doi: 10.3390/microorganisms9081752..

16. Roth R, Vavricka S, **Scharl M**, Schreiner P, Safroneeva E, Greuter T, Zeitz J, Misselwitz B, Schoepfer A, Barry MP, Rogler G, Biedermann L; Swiss IBD cohort study.  
*The impact of colectomy on the course of extraintestinal manifestations in Swiss inflammatory bowel disease cohort study patients.*  
United European Gastroenterol J. 2021 Aug 25;9(7):773-80. doi: 10.1002/ueg2.12125.
17. Lenggenhager D, Bengs S, Fritsch R, Hussung S, Busenhardt P, Endhardt K, Töpfer A, The FO, Bütikofer S, Gubler C, **Scharl M**, Morell B.  
 *$\beta$ 6-Integrin Serves as a Potential Serum Marker for Diagnosis and Prognosis of Pancreatic Adenocarcinoma.*  
Clin Transl Gastroenterol. 2021 Aug 13;12(8):e00395. doi: 10.14309/ctg.0000000000000395
18. Fazilaty H, Brügger MD, Valenta T, Szczerba BM, Berkova L, Doumpas N, Hausmann G, **Scharl M**, Basler K.  
*Tracing colonic embryonic transcriptional profiles and their reactivation upon intestinal damage.*  
Cell Rep. 2021 Aug 3;36(5):109484. doi: 10.1016/j.celrep.2021.109484
19. Yoganathan P, Rossel JB, Jordi SBU, Franc Y, Biedermann L, Misselwitz B, Hausmann M, Rogler G, **Scharl M**, Frey-Wagner I; Swiss IBD cohort study group.  
*Genotype-phenotype associations of polymorphisms within the gene locus of NOD-like receptor pyrin domain containing 3 in Swiss inflammatory bowel disease patients.*  
BMC Gastroenterol. 2021 Aug 3;21(1):310. doi: 10.1186/s12876-021-01880-9
20. Wawrzyniak M, Groeger D, Frei R, Ferstl R, Wawrzyniak P, Krawczyk K, Pugin B, Barcik W, Westermann P, Dreher A, **Scharl M**, Jutel M, Akdis CA, O Mahony L.  
*Spermidine and spermine exert protective effects within the lung.*  
Pharmacol Res Perspect. 2021 Aug;9(4):e00837. doi: 10.1002/prp2.837
21. Hering L, Katkeviciute E, Schwarzfischer M, Niechcial A, Riggs JB, Wawrzyniak M, Atrott K, van de Sande M, Lang S, Becher B, Rogler G, **Scharl M**, Spalinger MR.  
*Macrophages Compensate for Loss of Protein Tyrosine Phosphatase N2 in Dendritic Cells to Protect from Elevated Colitis.*  
Int J Mol Sci. 2021 Jun 25;22(13):6820. doi: 10.3390/ijms22136820.
22. Jordi SBU, Lang BM, Auschra B, von Känel R, Biedermann L, Greuter T, Schreiner P, Rogler G, Krupka N, Sulz MC, Misselwitz B, Begré S; **Swiss IBD Cohort Study Group.**  
*Depressive Symptoms Predict Clinical Recurrence of Inflammatory Bowel Disease.*  
Inflamm Bowel Dis. 2021 Jun 7;izab136. doi: 10.1093/ibd/izab136. Online ahead of print
23. Spalinger MR, Schwarzfischer M, Niechcial A, Atrott K, Laimbacher A, Gottier C, Lang S, **Scharl M**  
*Loss of PTPN22 promotes intestinal inflammation by compromising granulocyte-mediated anti-bacterial defense.*  
J Crohns Colitis. 2021 Dec 18;15(12):2118-2130. doi: 10.1093/ecco-jcc/jjab098
24. Jordi SBU, Botte F, Lang BM, Greuter T, Krupka N, Auschra B, Schreiner P, Sulz MC, Biedermann L, von Känel R, Rogler G, Begré S, Misselwitz B; **Swiss IBD cohort study group**  
*Type D personality is associated with depressive symptoms and clinical activity in inflammatory bowel disease.*

Aliment Pharmacol Ther. 2021 Jul;54(1):53-67. doi: 10.1111/apt.16365.

25. Reinhold I, Blümel S, Schreiner J, Boyman O, Bögeholz J, Cheetham M, Rogler G, Biedermann L, **Scharl M**.  
*Clinical Relevance of Anti-TNF Antibody Trough Levels and Anti-Drug Antibodies in Treating Inflammatory Bowel Disease Patients.*  
Inflamm Intest Dis. 2021 Feb;6(1):38-47. doi: 10.1159/000511296.
26. Manzini R, Schwarzfischer M, Atrott K, Laimbacher A, Lang S, Wawrzyniak M, Rickenbacher A, Turina M, Hruz P, Lissner D, Siegmund B, Rogler G, **Scharl M**, Spalinger MR.  
*Combination of Vedolizumab With Tacrolimus Is More Efficient Than Vedolizumab Alone in the Treatment of Experimental Colitis.*  
Inflamm Bowel Dis. 2021 Nov 15;27(12):1986-1998. doi: 10.1093/ibd/izab063
27. Villiger R, Cabalzar-Wondberg D, Zeller D, Frei P, Biedermann L, Schneider C, **Scharl M**, Rogler G, Turina M, Rickenbacher A, Misselwitz B  
*Perianal fistulodesis - A pilot study of a novel minimally invasive surgical and medical approach for closure of perianal fistulae.*  
World J Gastrointest Surg. 2021 Feb 27;13(2):187-197. doi: 10.4240/wjgs.v13.i2.187.
28. Wawrzyniak M, Morsy Y, Mladenov R, Tontodonati G, Turgay Y, Herwig S, Schneider J, Back J, Mally M, Faridmoayer A, **Scharl M**.  
*Fucosylation and sialylation of Fc-Fragment of anti-TNF alpha antibodies do not influence their immunogenicity in monocyte-derived dendritic cells.*  
J Crohns Colitis. 2021 Sep 25;15(9):1596-1601. doi: 10.1093/ecco-jcc/jjab038
29. Roth R., Safroneeva E, Saner Zilian C, Schreiner P, Rossel JB, Bopp M, Greuter T, **Scharl M**, Pittet V, Rogler G, Schoepfer A, Straumann A, Biedermann L  
*Higher educational level in patients with eosinophilic esophagitis: a comparative analysis*  
Dis Esophagus. 2021 Sep 9;34(9):doab010. doi: 10.1093/dote/doab010
30. Spalinger MR, Shawki A, Chatterjee P, Canale V, Santos A, Sayoc-Becerra A, **Scharl M**, Tremblay ML, Borneman J, McCole DF.  
*Autoimmune susceptibility gene PTPN2 is required for clearance of adherent-invasive Escherichia coli by integrating bacterial uptake and lysosomal defence.*  
Gut. 2022 Jan;71(1):89-99. doi: 10.1136/gutjnl-2020-323636. Epub 2021 Feb 9
31. Ledergerber M, Lang BM, Heinrich H, Biedermann L, Bègré S, Zeitz J, Krupka N, Rickenbacher A, Turina M, Greuter T, Schreiner P, Roth R, Siebenhüner A, Vavricka SR, Rogler G, Beerwinkel N, Misselwitz B; Swiss IBD Cohort Study Group.  
*Abdominal pain in patients with inflammatory bowel disease: association with single-nucleotide polymorphisms prevalent in irritable bowel syndrome and clinical management.*  
BMC Gastroenterol. 2021 Feb 5;21(1):53
32. Manzini R, Schwarzfischer M, Bircher A, Niechcial A, Vavricka SR, Atrott K, Lang S, **Scharl M**, Spalinger MR.  
*Energy Drink Administration Ameliorates Intestinal Epithelial Barrier Defects and Reduces Acute DSS Colitis.*  
Inflamm Bowel Dis. 2021 Jun 15;27(7):1139-1152. doi: 10.1093/ibd/izaa328

33. Conde J, Schwarzfischer M, Katkeviciute E, Häfliger J, Niechcial A, Brillant N, Manzini R, Bähler K, Atrott K, Lang S, **Scharl M**.  
*Titanium Dioxide Presents a Different Profile in Dextran Sodium Sulphate-Induced Experimental Colitis in Mice Lacking the IBD Risk Gene Ptpn2 in Myeloid Cells.*  
Int J Mol Sci. 2021 Jan 14;22(2):772. doi: 10.3390/ijms22020772.
34. Bruckner RS, Spalinger MR, Barnhoorn MC, Feakins R, Fuerst A, Jehle EC, Rickenbacher A, Turina M, Niechcial A, Lang S, Hawinkels LJAC, van der Meulen-de Jong AE, Verspaget HW, Rogler G, **Scharl M**.  
*Contribution of CD3+CD8- and CD3+CD8+ T Cells to TNF- $\alpha$  Overexpression in Crohn Disease-Associated Perianal Fistulas and Induction of Epithelial-Mesenchymal Transition in HT-29 Cells*  
Inflamm Bowel Dis. 2021 Mar 15;27(4):538-549. doi: 10.1093/ibd/izaa240.
35. Spalinger MR, Sayoc-Becerra A, Ordookhanian C, Canale V, Santos AN, King SJ, Krishnan M, Nair MG, **Scharl M**, McCole DF.  
*The JAK inhibitor tofacitinib rescues intestinal barrier defects caused by disrupted epithelial-macrophage interactions.*  
J Crohns Colitis. 2021 Mar 5;15(3):471-484. doi: 10.1093/ecco-jcc/jjaa182.
36. Lou PH, Lucchinetti E, Wawrzyniak P, Morsy Y, Wawrzyniak M, **Scharl M**, Krämer SD, Rogler G, Hersberger M, Zaugg M.  
*Choice of Lipid Emulsion Determines Inflammation of the Gut-Liver Axis, Incretin Profile, and Insulin Signaling in a Murine Model of Total Parenteral Nutrition.*  
Mol Nutr Food Res. 2021 Mar;65(5):e2000412. doi: 10.1002/mnfr.202000412.
37. Schreiner P, Rossel JB, Biedermann L, Valko PO, Baumann CR, Greuter T, **Scharl M**, Vavricka SR, Pittet V, Juillerat P, Rogler G, von Känel R, Misselwitz B; Swiss IBD Cohort Study Group.  
*Fatigue in inflammatory bowel disease and its impact on daily activities.*  
Aliment Pharmacol Ther. 2021 Jan;53(1):138-149. doi: 10.1111/apt.16145.
38. Katkeviciute E, Hering L, Montalban-Arques A, Busenhardt P, Schwarzfischer M, Manzini R, Conde J, Atrott K, Lang S, Rogler G, Naschberger E, Schellerer VS, Stürzl M, Rickenbacher A, Turina M, Weber A, Leibl S, Leventhal GE, Levesque M, Boyman O, **Scharl M**, Spalinger MR.  
*Protein tyrosine phosphatase non-receptor type 2 controls colorectal cancer development.*  
J Clin Invest. 2021 Jan 4;131(1):e140281. doi: 10.1172/JCI140281.
39. Lautenschlager SA, Fournier N, Biedermann L, Pittet V, Schreiner P, Misselwitz B, **Scharl M**, Rogler G, Siebenhüner AR..  
*The Influence of Breastfeeding, Cesarean Section, Pet Animals, and Urbanization on the Development of Inflammatory Bowel Disease: Data from the Swiss IBD Cohort Study.*  
Inflamm Intest Dis. 2020 Nov;5(4):170-179. doi: 10.1159/000509058.
40. Ditrich F, Blümel S, Biedermann L, Fournier N, Rossel JB, Ellinghaus D, Franke A, Stange EF, Rogler G, **Scharl M**; Swiss IBD Cohort Study Group..  
*Genetic risk factors predict disease progression in Crohn's disease patients of the Swiss inflammatory bowel disease cohort.*  
Therap Adv Gastroenterol. 2020 Nov 19;13:1756284820959252. doi: 10.1177/1756284820959252.

- 
41. Greuter T, Porchet F, Braga-Neto MB, Rossel JB, Biedermann L, Schreiner P, **Scharl M**, Schoepfer AM, Safroneeva E, Straumann A, Rogler G, Vavricka SR.  
*Impact of obesity on disease activity and disease outcome in inflammatory bowel disease: Results from the Swiss inflammatory bowel disease cohort.*  
United European Gastroenterol J. 2020 Dec;8(10):1196-1207. doi: 10.1177/2050640620954556.
42. Burla J, Bluemel S, Biedermann L, Barysch MJ, Dummer R, Levesque MP, Gubler C, Morell B, Rogler G, **Scharl M**.  
*Retrospective Analysis of Treatment and Complications of Immune Checkpoint Inhibitor-Associated Colitis: Histological Ulcerations as Potential Predictor for a Steroid-Refractory Disease Course.*  
Inflamm Intest Dis. 2020 Aug;5(3):109-116. doi: 10.1159/000507579.
43. Hering L, Katkeviciute E, Schwarzfischer M, Busenhardt P, Gottier C, Mrdjen D, Komuczki J, Wawrzyniak M, Lang S, Atrott K, Becher B, Rogler G, **Scharl M**, Spalinger MR.  
*Protein Tyrosine Phosphatase Non-Receptor Type 2 Function in Dendritic Cells Is Crucial to Maintain Tissue Tolerance.*  
Front Immunol. 2020 Aug 18;11:1856. doi: 10.3389/fimmu.2020.01856. eCollection 2020.
44. Merli AM, Vieujean S, Massot C, Blétard N, Quesada Calvo F, Baiwir D, Mazzucchelli G, Servais L, Wéra O, Oury C, de Leval L, Sempoux C, Manzini R, Bluemel S, **Scharl M**, Rogler G, De Pauw E, Coimbra Marques C, Colard A, Vijverman A, Delvenne P, Louis E, Meuwis MA.  
*Solute carrier family 12 member 2 as a proteomic and histological biomarker of dysplasia and neoplasia in ulcerative colitis.*  
J Crohns Colitis. 2020 Sep 13;jjaa168. doi: 10.1093/ecco-jcc/jjaa168. Online ahead of print.
45. Spalinger MR, Sayoc-Becerra A, Santos AN, Shawki A, Canale V, Krishnan M, Niechcial A, Obialo N, **Scharl M**, Li J, Nair MG, McCole DF.  
*PTPN2 Regulates Interactions Between Macrophages and Intestinal Epithelial Cells to Promote Intestinal Barrier Function.*  
Gastroenterology. 2020 Nov;159(5):1763-1777.e14. doi: 10.1053/j.gastro.2020.07.004. Epub 2020 Jul 9
46. Ortiz-Masiá D, Gisbert-Ferrándiz L, Bauset C, Coll S, Mamie C, **Scharl M**, Esplugues JV, Alós R, Navarro F, Cosín-Roger J, Barrachina MD, Calatayud S.  
*Succinate Activates EMT in Intestinal Epithelial Cells through SUCNR1: A Novel Protagonist in Fistula Development.*  
Cells. 2020 Apr 29;9(5):1104. doi: 10.3390/cells9051104.
47. Wuggenig P, Kaya B, Melhem H, Ayata CK; **Swiss IBD Cohort Investigators**, Hruz P, Sayan AE, Tsumura H, Ito M, Roux J, Niess JH.  
*Loss of the branched-chain amino acid transporter CD98hc alters the development of colonic macrophages in mice.*  
Commun Biol. 2020 Mar 18;3(1):130. doi: 10.1038/s42003-020-0842-3
48. Sowińska A, Morsy Y, Czarnowska E, Oralewska B, Konopka E, Woynarowski M, Szymańska S, Ejmont M, **Scharl M**, Bierła JB, Wawrzyniak M, Cukrowska B.  
*Transcriptional and Ultrastructural Analyses Suggest Novel Insights into Epithelial Barrier Impairment in Celiac Disease.*  
Cells. 2020 Feb 24;9(2). pii: E516. doi: 10.3390/cells9020516.

49. Serra EG, Schwerd T, Moutsianas L, Cavounidis A, Fachal L, Pandey S, Kammermeier J, Croft NM, Posovszky C, Rodrigues A, Russell RK, Barakat F, Auth MKH, Heuschkel R, Zilbauer M, Fyderek K, Braegger C, Travis SP, Satsangi J, Parkes M, Thapar N, Ferry H, Matte JC, Gilmour KC, Wedrychowicz A, Sullivan P, Moore C, Sambrook J, Ouwehand W, Roberts D, Danesh J, Baeumler TA, Fulga TA, Karaminejadranjbar M, Ahmed A, Wilson R, Barrett JC, Elkadri A, Griffiths AM; **Swiss IBD cohort investigators**; Oxford IBD cohort study investigators; INTERVAL Study; **Swiss IBD cohort investigators**; UK IBD Genetics Consortium; NIDDK IBD Genetics Consortium, Snapper SB, Shah N, Muise AM, Wilson DC, Uhlig HH, Anderson CA.  
*Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease.*  
Nat Commun. 2020 Feb 21;11(1):995. doi: 10.1038/s41467-019-14275-y
50. Sabev M, Blümel S, Lang S, Gottier C, Weber A, Mertens J, Müllhaupt B, **Scharl M**, Spalinger MR  
*Protein Tyrosine Phosphatase Nonreceptor Type 2 Expression Does Not Correlate with Viral Load or Response to Direct-Acting Antiviral Therapy in Hepatitis C Virus Infections-Infected Patients.*  
Digestion. 2020 Feb 19:1-9. doi: 10.1159/000505645
51. Grob L, Blümel S, Biedermann L, Fournier N, Rossel JB, Vavricka SR, Zeitz J, Rogler G, Stallmach A, **Scharl M**  
*Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study.*  
Therap Adv Gastroenterol. 2020 Jan 24;13:1756284819895217. doi: 10.1177/1756284819895217
52. Niechcial A, Butter M, Manz S, Obialo N, Bähler K, van der Lely L, Lang S, Gottier C, McCole DF, **Scharl M**, Spalinger MR.  
*Presence of PTPN2 SNP rs1893217 Enhances the Anti-inflammatory Effect of Spermidine.*  
Inflamm Bowel Dis. 2020 Jun 18;26(7):1038-1049. doi: 10.1093/ibd/izaa013
53. Maeyashiki C, Melhem H, Hering L, Bähler K, Cosin-Roger J, Schefer F, Weder B, Hausmann M, **Scharl M**, Rogler G, de Vallière C, Ruiz PA.  
*Activation of pH-Sensing Receptor OGR1 (GPR68) Induces ER Stress Via the IRE1 $\alpha$ /JNK Pathway in an Intestinal Epithelial Cell Model.*  
Sci Rep. 2020 Jan 29;10(1):1438. doi: 10.1038/s41598-020-57657-9.
54. Ortiz-Masià D, Salvador P, Macias-Ceja DC, Gisbert-Ferrándiz L, Esplugues JV, Manyé J, Alós R, Navarro-Vicente F, Mamie C, **Scharl M**, Cosin-Roger J, Calatayud S, Barrachina MD.  
*WNT2b activates epithelial-mesenchymal transition through FZD4: relevance in penetrating Crohn's disease*  
J Crohns Colitis. 2020 Feb 10;14(2):230-239. doi: 10.1093/ecco-jcc/jjz134.
55. Cernoch PS, Fournier N, Zeitz J, **Scharl M**, Morell B, Greuter T, Schreiner P, Misselwitz B, Safroneeva E, Schoepfer AM, Vavricka SR, Rogler G, Biedermann L; Swiss IBD Cohort Study Group.  
*Lower Risk of B1-to-pB3-Stage Migration in Crohn's Disease Upon Immunosuppressive and Anti-TNF Treatment in the Swiss IBD Cohort Study.*  
Dig Dis Sci. 2020 Sep;65(9):2654-2663. doi: 10.1007/s10620-019-05978-9. Epub 2019 Dec 3
56. Spalinger MR, Schwarzfischer M, Hering L, Shawki A, Sayoc A, Santos A, Gottier C, Lang S, Bähler K, Geirnaert A, Lacroix C, Leventhal GE, Dai X, Rawlings D, Chan AA, Rogler G, McCole DF, **Scharl M**.  
*Loss of PTPN22 abrogates the beneficial effect of cohousing-mediated fecal microbiota transfer in murine colitis.*

Mucosal Immunol. 2019 Nov;12(6):1336-1347. doi: 10.1038/s41385-019-0201-1.

57. van der Lely L, Häfliger J, Montalban-Arques A, Bäbler K, Schwarzfischer M, Sabev M, Gottier C, Lang S, **Scharl M**, Spalinger MR.  
*Loss of PTPN23 Promotes Proliferation and Epithelial-to-Mesenchymal Transition in Human Intestinal Cancer Cells.*  
Inflamm Intest Dis. 2019 Oct;4(4):161-173. doi: 10.1159/000502861.
58. Frei R, Fournier N, Zeitz J, **Scharl M**, Morell B, Greuter T, Schreiner P, Misselwitz B, Safroneeva E, Schoepfer AM, Vavricka SR, Rogler G, Biedermann L.  
*Early Initiation of Anti-TNF is Associated with Favourable Long-term Outcome in Crohn's Disease: 10-Year-Follow-up Data from the Swiss IBD Cohort Study.*  
J Crohns Colitis. 2019 Sep 27;13(10):1292-1301. doi: 10.1093/ecco-jcc/ijz057
59. Humbel F, Rieder JH, Franc Y, Juillerat P, **Scharl M**, Misselwitz B, Schreiner P, Begré S, Rogler G, von Känel R, Yilmaz B, Biedermann L; Swiss IBD Cohort Study Group  
*Association of Alterations in Intestinal Microbiota With Impaired Psychological Function in Patients With Inflammatory Bowel Diseases in Remission*  
Clin Gastroenterol Hepatol. 2020 Aug;18(9):2019-2029.e11. doi: 10.1016/j.cgh.2019.09.022. Epub 2019 Sep 20.
60. Raselli T, Wyss A, Gonzalez Alvarado MN, Weder B, Mamie C, Spalinger MR, Van Haaften WT, Dijkstra G, Sailer AW, Imenez Silva PH, Wagner CA, Tosevski V, Leibl S, **Scharl M**, Rogler G, Hausmann M, Misselwitz B.  
*The Oxysterol Synthesising Enzyme CH25H Contributes to the Development of Intestinal Fibrosis*  
J Crohns Colitis. 2019 Sep 19;13(9):1186-1200
61. Biedermann L, Renz L, Fournier N, Rossel JB, Butter M, Bluemel S, Vavricka SR, Rogler G, **Scharl M**.  
*Uveitis manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study*  
Therap Adv Gastroenterol. 2019 Aug 13;12:1756284819865142. doi: 10.1177/1756284819865142.
62. King SJ, Bunz M, Chappell A, **Scharl M**, Docherty M, Jung B, Lytle C, McCole DF.  
*AMPK mediates inhibition of electrolyte transport and NKCC1 activity by reactive oxygen species.*  
Am J Physiol Gastrointest Liver Physiol. 2019 Aug 1;317(2):G171-G181.
63. Bengs S, Becker E, Busenhardt P, Spalinger MR, Raselli T, Kasper S, Lang S, Atrott K, Mamie C, Vavricka SR, von Boehmer L, Knuth A, Tuomisto A, Mäkinen MJ, Hruz P, Turina M, Rickenbacher A, Petrowsky H, Weber A, Frei P, Halama M, Jenkins G, Sheppard D, Croner RS, Christoph J, Britzen-Laurent N, Naschberger E, Schellerer V, Stürzl M, Fried M, Rogler G, **Scharl M**.  
*β6-integrin serves as a novel serum tumor marker for colorectal carcinoma*  
Int J Cancer. 2019 Aug 1;145(3):678-685.
64. Zapater P, Almenara S, Gutiérrez A, Sempere L, García M, Laveda R, Martínez A, **Scharl M**, Cameo JI, Linares R, González-Navajas JM, Wiest R, Rogler G, Francés R.  
*Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease*  
Inflamm Bowel Dis. 2019 Jul 17;25(8):1357-1366.



65. Raselli T, Hearn T, Wyss A, Atrott K, Peter A, Frey-Wagner I, Spalinger MR, Maggio EM, Sailer AW, Schmitt J, Schreiner P, Moncsek A, Mertens J, **Scharl M**, Griffiths WJ, Bueter M, Geier A, Rogler G, Wang Y, Misselwitz B.  
*Elevated oxysterol levels in human and mouse livers reflect nonalcoholic steatohepatitis*  
J Lipid Res. 2019 Jul;60(7):1270-1283.
66. Schreiner P, Yilmaz B, Rossel JB, Franc Y, Misselwitz B, **Scharl M**, Zeitz J, Frei P, Greuter T, Vavricka SR, Pittet V, Siebenhüner A, Juillera P, von Känel R, Macpherson AJ, Rogler G, Biedermann L; Swiss IBD Cohort Study Group.  
*Vegetarian or gluten-free diets in patients with inflammatory bowel disease are associated with lower psychological well-being and a different gut microbiota, but no beneficial effects on the course of the disease*  
United European Gastroenterol J. 2019 Jul;7(6):767-781.
67. Poeker SA, Lacroix C, de Wouters T, Spalinger MR, **Scharl M**, Geirnaert A.  
*Stepwise Development of an in vitro Continuous Fermentation Model for the Murine Caecal Microbiota*  
Front Microbiol. 2019 May 29;10:1166.
68. Spalinger MR, Atrott K, Baebler K, Schwarzfischer M, Melhem H, Peres DR, Lalazar G, Rogler G, **Scharl M**, Frey-Wagner I.  
*Administration of the Hyper-immune Bovine Colostrum Extract IMM-124E Ameliorates Experimental Murine Colitis*  
J Crohns Colitis. 2019 May 27;13(6):785-797.
69. Bruckner RS, Nissim-Eliraz E, Marsiano N, Nir E, Shemesh H, Leutenegger M, Gottier C, Lang S, Spalinger MR, Leibl S, Rogler G, Yagel S, **Scharl M**, Shpigel NY.  
*Transplantation of Human Intestine Into the Mouse: A Novel Platform for Study of Inflammatory Enterocutaneous Fistulas*  
J Crohns Colitis. 2019 May 27;13(6):798-806.
70. Spalinger MR, Schmidt TS, Schwarzfischer M, Hering L, Atrott K, Lang S, Gottier C, Geirnaert A, Lacroix C, Dai X, Rawlings DJ, Chan AC, von Mering C, Rogler G, **Scharl M**.  
*Protein tyrosine phosphatase non-receptor type 22 modulates colitis in a microbiota-dependent manner*  
J Clin Invest. 2019 May 20;129(6):2527-2541.
71. Ulugöl S, Hering L, Manzini R, Montalban Arques A, Gottier C, Lang S, **Scharl M**, Spalinger MR.  
*Deletion of Protein Tyrosine Phosphatase Nonreceptor Type 2 in Intestinal Epithelial Cells Results in Upregulation of the Related Phosphatase Protein Tyrosine Phosphatase Nonreceptor Type 23*  
Inflamm Intest Dis. 2019 May;4(1):14-26.
72. Wyss A, Raselli T, Perkins N, Ruiz F, Schmelczer G, Klinke G, Moncsek A, Roth R, Spalinger MR, Hering L, Atrott K, Lang S, Frey-Wagner I, Mertens JC, **Scharl M**, Sailer AW, Pabst O, Hersberger M, Pot C, Rogler G, Misselwitz B.  
*The EBI2-oxysterol axis promotes the development of intestinal lymphoid structures and colitis*  
Mucosal Immunol. 2019 May;12(3):733-745.
73. Hiller A, Biedermann L, Fournier N, Butter M, Vavricka SR, Ciurea A, Rogler G, **Scharl M**; Swiss IBD Cohort Study Group.  
*The appearance of joint manifestations in the Swiss inflammatory bowel disease cohort*

PLoS One. 2019 Apr 30;14(4):e0211554.

74. Bon L, Scharl S, Vavricka S, Rogler G, Fournier N, Pittet V, **Scharl M**, Greuter T, Schreiner P, Frei P, Misselwitz B, Biedermann L, Zeitz J; Swiss IBD Cohort Study Group.  
*Association of IBD specific treatment and prevalence of pain in the Swiss IBD cohort study*  
PLoS One. 2019 Apr 25;14(4):e0215738
  
75. Frei R, Fournier N, Zeitz J, **Scharl M**, Morell B, Greuter T, Schreiner P, Misselwitz B, Safroneeva E, Schoepfer AM, Vavricka SR, Rogler G, Biedermann L; Swiss IBD Cohort Study Group.  
*Early Initiation of Anti-Tnf is Associated with Favourable Long-Term Outcome in Crohn's Disease: 10-Year-Follow-Up Data from the Swiss IBD Cohort Study.*  
J Crohns Colitis. 2019 Mar 7. pii: jjz057.
  
76. Mürner CM, Stenner-Liewen F, Seifert B, Mueller NJ, Schmidt A, Renner C, Schanz U, Knuth A, Manz MG, **Scharl M**, Gerber B, Samaras P.  
*Efficacy of selective digestive decontamination in patients with multiple myeloma undergoing high-dose chemotherapy and autologous stem cell transplantation.*  
Leuk Lymphoma. 2019 Mar;60(3):685-695.
  
77. Bardenbacher M, Ruder B, Britzen-Laurent N, Schmid B, Waldner M, Naschberger E, **Scharl M**, Müller W, Günther C, Becker C, Stürzl M, Tripal P.  
*Permeability analyses and three dimensional imaging of interferon gamma-induced barrier disintegration in intestinal organoids*  
Stem Cell Res. 2019 Mar;35:101383.
  
78. Tcymbarevich I, Richards SM, Russo G, Kühn-Georgijevic J, Cosin-Roger J, Baebler K, Lang S, Bengs S, Atrott K, Bettoni C, Gruber S, Frey-Wagner I, **Scharl M**, Misselwitz B, Wagner CA, Seuwen K, Rogler G, Ruiz PA, Spalinger M, de Vallière C.  
*Lack of the pH-sensing Receptor TDAG8 [GPR65] in Macrophages Plays a Detrimental Role in Murine Models of Inflammatory Bowel Disease*  
J Crohns Colitis. 2019 Feb 1;13(2):245-258.
  
79. Roth N, Biedermann L, Fournier N, Butter M, Vavricka SR, Navarini AA, Rogler G, **Scharl M**; Swiss IBD Cohort Study Group.  
*Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study*  
PLoS One. 2019 Jan 25;14(1):e0210436.
  
80. Tcymbarevich IV, Eloranta JJ, Rossel JB, Obialo N, Spalinger M, Cosin-Roger J, Lang S, Kullak-Ublick GA, Wagner CA, **Scharl M**, Seuwen K, Ruiz PA, Rogler G, de Vallière C, Misselwitz B; Swiss IBD Cohort Study Group.  
*The impact of the rs8005161 polymorphism on G protein-coupled receptor GPR65 (TDAG8) pH-associated activation in intestinal inflammation.*  
BMC Gastroenterol. 2019 Jan 7;19(1):2.
  
81. Scharl S, Barthel C, Rossel JB, Biedermann L, Misselwitz B, Schoepfer AM, Straumann A, Vavricka SR, Rogler G, **Scharl M**, Greuter T.  
*Malignancies in Inflammatory Bowel Disease: Frequency, Incidence and Risk Factors-Results from the Swiss IBD Cohort Study.*  
Am J Gastroenterol. 2019 Jan;114(1):116-126.

82. Simmen S, Cosin-Roger J, Melhem H, Maliachovas N, Maane M, Baebler K, Weder B, Maeyashiki C, Spanaus K, **Scharl M**, de Vallière C, Zeitz J, Vavricka SR, Hausmann M, Rogler G, Ruiz PA. *Iron Prevents Hypoxia-Associated Inflammation Through the Regulation of Nuclear Factor- $\kappa$ B in the Intestinal Epithelium.* Cell Mol Gastroenterol Hepatol. 2019;7(2):339-355.
83. Greuter T, Piller A, Fournier N, Safroneeva E, Straumann A, Biedermann L, Godat S, Nydegger A, **Scharl M**, Rogler G, Vavricka SR, Schoepfer AM; Swiss IBD Cohort Study Group. *Upper Gastrointestinal Tract Involvement in Crohn's Disease: Frequency, Risk Factors, and Disease Course.* J Crohns Colitis. 2018 Nov 28;12(12):1399-1409.
84. Wotzka SY, Kreuzer M, Maier L, Zünd M, Schlumberger M, Nguyen B, Fox M, Pohl D, Heinrich H, Rogler G, Biedermann L, **Scharl M**, Sunagawa S, Hardt WD, Misselwitz B. *Microbiota stability in healthy individuals after single-dose lactulose challenge-A randomized controlled study* PLoS One. 2018 Oct 25;13(10):e0206214.
85. Vavricka Sr, Heinrich H, Buetikofer S, Breitenmoser F, Burri E, Schneider-Ain X, Barman-Aksoezen J, Biedermann L, **Scharl M**, Zeitz J, Rogler G, Misselwitz B, Sauter M *The Vampire Study: Significant elevation of faecal calprotectin in healthy volunteers after 300 ml blood ingestion mimicking upper gastrointestinal bleeding* United European Gastroenterology Journal. 2018 Aug 6;7:1007-1014
86. Yilmaz B, Spalinger MR, Biedermann L, Franc Y, Fournier N, Rossel JB, Juillerat P, Rogler G, Macpherson AJ, **Scharl M**. *The presence of genetic risk variants within PTPN2 and PTPN22 is associated with intestinal microbiota alterations in Swiss IBD cohort patients.* PLoS One. 2018 Jul 2;13(7):e0199664.
87. Madanchi M, Fagagnini S, Fournier N, Biedermann L, Zeitz J, Battegay E, Zimmerli L, Vavricka SR, Rogler G, **Scharl M**; Swiss IBD Cohort Study Group . *The Relevance of Vitamin and Iron Deficiency in Patients with Inflammatory Bowel Diseases in Patients of the Swiss IBD Cohort.* Inflamm Bowel Dis. 2018 Jul 12;24(8):1768-1779
88. Parragi L, Fournier N, Zeitz J, **Scharl M**, Greuter T, Schreiner P, Misselwitz B, Safroneeva E, Schoepfer AM, Vavricka SR, Rogler G, Biedermann L; Swiss IBD Cohort Study Group *Colectomy Rates in Ulcerative Colitis are Low and Decreasing: 10-year Follow-up Data From the Swiss IBD Cohort Study.* J Crohns Colitis. 2018 Jun 28;12(7):811-818.
89. Herzog D, Fournier N, Buehr P, Rueger V, Koller R, Heyland K, Nydegger A, Spalinger J, Schibli S, Petit LM, Braegger CP; **Swiss IBD Cohort Study Group**. *Age at disease onset of inflammatory bowel disease is associated with later extraintestinal manifestations and complications.* Eur J Gastroenterol Hepatol. 2018 Jun;30(6):598-607

- 
90. Godat S, Fournier N, Safroneeva E, Juillerat P, Nydegger A, Straumann A, Vavricka S, Biedermann L, Greuter T, Fraga M, Abdelrahman K, Hahnloser D, Sauter B, Rogler G, Michetti P, Schoepfer AM; **Swiss IBD Cohort Study Group**. *Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort*. Eur J Gastroenterol Hepatol. 2018 Jun;30(6):612-620
91. Burisch J, Gisbert JP, Siegmund B, Bettenworth D, Thomsen SB, Cleynen I, Cremer A, Ding NJS, Furfaro F, Galanopoulos M, Grunert PC, Hanzel J, Ivanovski TK, Krustins E, Noor N, O'Morain N, Rodríguez-Lago I, **Scharl M**, Tua J, Uzzan M, Ali Yassin N, Baert F, Langholz E. *Validation of the 'United Registries for Clinical Assessment and Research' [UR-CARE], a European Online Registry for Clinical Care and Research in Inflammatory Bowel Disease*. J Crohns Colitis. 2018 Apr 27;12(5):532-537
92. Nagy N, Marsiano N, Bruckner RS, **Scharl M**, Gutnick MJ, Yagel S, Arciero E, Goldstein AM, Shpigel NY. *Xenotransplantation of human intestine into mouse abdomen or subcutaneous tissue: Novel platforms for the study of the human enteric nervous system*. Neurogastroenterol Motil. 2018 Mar;30(3):10.1111/nmo.13212.
93. Greuter T, Franc Y, Kaelin M, Schoepfer AM, Schreiner P, Zeitz J, **Scharl M**, Misselwitz B, Straumann A, Vavricka SR, Rogler G, von Känel R, Biedermann L. *Low serum zinc levels predict presence of depression symptoms, but not overall disease outcome, regardless of ATG16L1 genotype in Crohn's disease patients*. Therap Adv Gastroenterol. 2018 Feb 19;11:1756283X18757715
94. Cosin-Roger J, Spalinger MR, Ruiz PA, Stanzel C, Terhalle A, Wolfram L, Melhem H, Atrott K, Lang S, Frey-Wagner I, Fried M, **Scharl M**, Hausmann M, Rogler G. *Gp96 deficiency affects TLR4 functionality and impairs ERK and p38 phosphorylation*. PLoS One. 2018 Feb 15;13(2):e0193003
95. Spalinger MR, Manzini R, Hering L, Riggs JB, Gottier C, Lang S, Atrott K, Fettelschoss A, Olomski F, Kündig TM, Fried M, McCole DF, Rogler G, **Scharl M**. *PTPN2 Regulates Inflammasome Activation and Controls Onset of Intestinal Inflammation and Colon Cancer*. Cell Rep. 2018 Feb 13;22(7):1835-1848
96. Vavricka SR, Galván JA, Dawson H, Soltermann A, Biedermann L, **Scharl M**, Schoepfer AM, Rogler G, Prinz Vavricka MB, Terracciano L, Navarini A, Zlobec I, Lugli A, Greuter T. *Expression Patterns of TNF $\alpha$ , MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease*. J Crohns Colitis. 2018 Feb 28;12(3):347-354.
97. Lang BM, Biedermann L, van Haaften WT, de Vallière C, Schuurmans M, Bègré S, Zeitz J, **Scharl M**, Turina M, Greuter T, Schreiner P, Heinrich H, Kuntzen T, Vavricka SR, Rogler G, Beerenwinkel N, Misselwitz B; Swiss IBD Cohort Study Group. *Genetic polymorphisms associated with smoking behaviour predict the risk of surgery in patients with Crohn's disease*. Aliment Pharmacol Ther. 2018 Jan;47(1):55-66

- 
98. Vavricka SR, Stelzer T, Lattmann J, Stotz M, Lehmann R, Zeitz J, **Scharl M**, Misselwitz B, Pohl D, Fried M, Tutuian R, Fasano A, Schoepfer AM, Rogler G, Biedermann L, Greuter T.  
*Celiac Disease is Misdiagnosed Based on Serology Only in a Substantial Proportion of Patients.*  
J Clin Gastroenterol. 2018 Jan;52(1):25-29
99. Fagagnini S, Heinrich H, Rossel JB, Biedermann L, Frei P, Zeitz J, Spalinger M, Battegay E, Zimmerli L, Vavricka SR, Rogler G, **Scharl M**, Misselwitz B.  
*Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases.*  
PLoS One. 2017 Oct 12;12(10):e0185193
100. Spalinger MR, Lang S, Gottier C, Dai X, Rawlings DJ, Chan AC, Rogler G, **Scharl M**.  
*PTPN22 regulates NLRP3-mediated IL1B secretion in an autophagy-dependent manner.*  
Autophagy. 2017 Sep 2;13(9):1590-1601
101. Greuter T, Bertoldo F, Rechner R, Straumann A, Biedermann L, Zeitz J, Misselwitz B, **Scharl M**, Rogler G, Safroneeva E, Ali RAR, Braegger C, Heyland K, Mueller P, Nydegger A, Petit LM, Schibli S, Furlano RI, Spalinger J, Schäppi M, Zamora S, Froehlich F, Herzog D, Schoepfer AM, Vavricka SR; Swiss IBD Cohort Study Group.  
*Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease: Prevalence, Presentation, and Anti-TNF Treatment.*  
J Pediatr Gastroenterol Nutr. 2017 Aug;65(2):200-206
102. Ruiz PA, Morón B, Becker HM, Lang S, Atrott K, Spalinger MR, **Scharl M**, Wojtal KA, Fischbeck-Terhalle A, Frey-Wagner I, Hausmann M, Kraemer T, Rogler G.  
*Titanium dioxide nanoparticles exacerbate DSS-induced colitis: role of the NLRP3 inflammasome.*  
Gut. 2017 Jul;66(7):1216-1224
103. Vavricka SR, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, Protic M, Michetti P, Straumann A, Fournier N, Juillerat P, Biedermann L, Zeitz J, Misselwitz B, **Scharl M**, Heinrich H, Manser CN, Safroneeva E, Raja Ali RA, Rogler G, Schoepfer AM, Greuter T; Swiss IBD Cohort Study Group.  
*Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study.*  
Inflamm Bowel Dis. 2017 Jul;23(7):1174-1181
104. Schüle S, Rossel JB, Frey D, Biedermann L, **Scharl M**, Zeitz J, Freitas-Queiroz N, Kuntzen T, Greuter T, Vavricka SR, Rogler G, Misselwitz B; Swiss IBD cohort study.  
*Widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD cohort study.*  
Medicine (Baltimore). 2017 Jun;96(22):e6788
105. Vavricka SR, Spasojevic M, Rogler G, Schoepfer AM, Seibold F, Borovicka J, Frei P, Zeitz J, Greuter T, Manser C, **Scharl M**, Misselwitz B, Straumann A, Michetti P, Biedermann L; Swiss IBDnet.  
*Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey.*  
Dig Dis. 2017;35(5):423-432
106. Zeitz J, Fournier N, Labenz C, Biedermann L, Frei P, Misselwitz B, Scharl S, Vavricka SR, Sulz MC, Fried M, Rogler G, **Scharl M**.

*Risk Factors for the Development of Fistulae and Stenoses in Crohn Disease Patients in the Swiss Inflammatory Bowel Disease Cohort.*  
Inflamm Intest Dis. 2017 Apr;1(4):172-181

107. Greuter T, Schmidlin S, Lattmann J, Stotz M, Lehmann R, Zeitz J, **Scharl M**, Misselwitz B, Pohl D, Fried M, Tutian R, Fasano A, Schoepfer AM, Rogler G, Biedermann L, Vavricka SR  
*The perspective of celiac disease patients on emerging treatment options and non-celiac gluten sensitivity*  
Dig Liver Dis. 2017 Mar, 49(3):268-272
108. Zeitz J, Bissig M, Barthel C, Biedermann L, Scharl S, Pohl D, Frei P, Vavricka SR, Fried M, Rogler G, **Scharl M**.  
*Patients' views on fecal microbiota transplantation: an acceptable therapeutic option in inflammatory bowel disease?*  
Eur J Gastroenterol Hepatol. 2017 Mar;29(3):322-330
109. Pittet V, Vaucher C, Froehlich F, Burnand B, Michetti P, Maillard MH; **Swiss IBD Cohort Study Group**.  
*Patient self-reported concerns in inflammatory bowel diseases: A gender-specific subjective quality-of-life indicator.*  
PLoS One. 2017 Feb 10;12(2):e0171864.
110. Vavricka S, Ruiz PA, Scharl S, Biedermann L, **Scharl M**, de Vallière C, Lundby C, Wenger RH, Held L, Merz TM, Gassmann M, Lutz T, Kunz A, Bron D, Fontana A, Strauss L, Weber A, Fried M, Rogler G, Zeitz J.  
*Protocol for a prospective, controlled, observational study to evaluate the influence of hypoxia on healthy volunteers and patients with inflammatory bowel disease: the Altitude IBD Study.*  
BMJ Open. 2017 Jan 5;7(1):e013477
111. Bontà J, Zeitz J, Frei P, Biedermann L, Sulz MC, Vavricka SR, Scharl S, Fried M, Rogler G, **Scharl M**.  
*Cytomegalovirus disease in inflammatory bowel disease: epidemiology and disease characteristics in a large single-centre experience.*  
Eur J Gastroenterol Hepatol. 2016 Nov;28(11):1329-34.
112. Schüle S, Rossel JB, Frey D, Biedermann L, **Scharl M**, Zeitz J, Freitas-Queiroz N, Pittet V, Vavricka SR, Rogler G, Misselwitz B; Swiss IBD cohort study.  
*Prediction of low bone mineral density in patients with inflammatory bowel diseases.*  
United European Gastroenterol J. 2016 Oct;4(5):669-676
113. Vavricka SR, Vadasz N, Stotz M, Lehmann R, Studerus D, Greuter T, Frei P, Zeitz J, **Scharl M**, Misselwitz B, Pohl D, Fried M, Tutian R, Fasano A, Schoepfer AM, Rogler G, Biedermann L.  
*Celiac disease diagnosis still significantly delayed - Doctor's but not patients' delay responsive for the increased total delay in women.*  
Dig Liver Dis. 2016 Oct;48(10):1148-54.
114. Goffin L, Fagagnini S, Vicari A, Mamie C, Melhem H, Weder B, Lutz C, Lang S, **Scharl M**, Rogler G, Chvatchko Y, Hausmann M.  
*Anti-MMP-9 Antibody: A Promising Therapeutic Strategy for Treatment of Inflammatory Bowel Disease Complications with Fibrosis.*  
Inflamm Bowel Dis. 2016 Sep;22(9):2041-57

115. Spalinger MR, Zeitz J, Biedermann L, Rossel JB, Sulz MC, Frei P, Scharl S, Vavricka SR, Fried M, Rogler G, **Scharl M**; Swiss IBD Cohort Study Group.  
*Genotype-Phenotype Associations of the CD-Associated Single Nucleotide Polymorphism within the Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 22 in Patients of the Swiss IBD Cohort.*  
PLoS One. 2016 Jul 28;11(7):e0160215
116. Zeitz J, Ak M, Müller-Mottet S, Scharl S, Biedermann L, Fournier N, Frei P, Pittet V, **Scharl M**, Fried M, Rogler G, Vavricka S; Swiss IBD Cohort Study Group.  
*Pain in IBD Patients: Very Frequent and Frequently Insufficiently Taken into Account.*  
PLoS One. 2016 Jun 22;11(6):e0156666.
117. Madanchi M, Zeitz J, Barthel C, Samaras P, Scharl S, Sulz MC, Biedermann L, Frei P, Vavricka SR, Rogler G, **Scharl M**.  
*Malignancies in Patients with Inflammatory Bowel Disease: A Single-Centre Experience.*  
Digestion. 2016;94(1):1-8
118. Spalinger MR, Kasper S, Gottier C, Lang S, Atrott K, Vavricka SR, Scharl S, Raselli T, Frey-Wagner I, Gutte PM, Grütter MG, Beer HD, Contassot E, Chan AC, Dai X, Rawlings DJ, Mair F, Becher B, Falk W, Fried M, Rogler G, **Scharl M**.  
*NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22.*  
J Clin Invest. 2016 Mai;126(5):1783-800.
119. Vögelin M, Biedermann L, Frei P, Vavricka SR, Scharl S, Zeitz J, Sulz MC, Fried M, Rogler G, **Scharl M**.  
*The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease.*  
PLoS One. 2016 May 23;11(5):e0155218
120. Roth S, Spalinger MR, Gottier C, Biedermann L, Zeitz J, Lang S, Weber A, Rogler G, **Scharl M**.  
*Bilberry-Derived Anthocyanins Modulate Cytokine Expression in the Intestine of Patients with Ulcerative Colitis.*  
PLoS One. 2016 May 6;11(5):e0154817
121. Kasper SH, Spalinger MR, Leonardi I, Gerstgrasser A, Raselli T, Gottier C, Atrott K, Frey-Wagner I, Fischbeck-Terhalle A, Rogler G, **Scharl M**.  
*Deficiency of Protein Tyrosine Phosphatase Non-Receptor Type 2 in Intestinal Epithelial Cells Has No Appreciable Impact on Dextran Sulphate Sodium Colitis Severity But Promotes Wound Healing.*  
Digestion. 2016;93(4):249-59
122. Spalinger MR, Voegelin M, Biedermann L, Zeitz J, Rossel JB, Sulz MC, Frei P, Scharl S, Vavricka SR, Fried M, Rogler G, **Scharl M**; Swiss IBD Cohort Study Group.  
*The Clinical Relevance of the IBD-Associated Variation within the Risk Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 2 in Patients of the Swiss IBD Cohort.*  
Digestion. 2016; 93(3):182-92.
123. Gutiérrez A, Zapater P, Juanola O, Sempere L, García M, Laveda R, Martínez A, **Scharl M**, González-Navajas JM, Such J, Wiest R, Rogler G, Francés R.

*Gut Bacterial DNA Translocation is an Independent Risk Factor of Flare at Short Term in Patients With Crohn's Disease.*

Am J Gastroenterol. 2016 Apr;111(4):529-40

124. Mueller R, Ziade F, Pittet V, Fournier N, Ezri J, Schoepfer A, Schibli S, Spalinger J, Braegger C, Nydegger A; **Swiss IBD Cohort Study**. *Quality of Life in Swiss Paediatric Inflammatory Bowel Disease Patients: Do Patients and Their Parents Experience Disease in the Same Way?* J Crohns Colitis. 2016 Mar;10(3):269-76
125. Kiessling MK, Curioni-Fontecedro A, Samaras P, Lang S, **Scharl M**, Aguzzi A, Oldrige DA, Maris JM, Rogler G. *Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma.* PLoS One. 2016 Jan 28;11(1):e0147682.
126. Kiessling MK, Curioni-Fontecedro A, Samaras P, Atrott K, Cosin-Roger J, Lang S, **Scharl M**, Rogler G. *Mutant HRAS as novel target for MEK and mTOR inhibitors.* Oncotarget. 2015 Dec 8;6(39):42183-96
127. Aradi B, Kato M, Filkova M, Karouzakis E, Klein K, **Scharl M**, Kolling C, Michel BA, Gay RE, Buzas EI, Gay S, Jüngel A. *Protein tyrosine phosphatase nonreceptor type 2: an important regulator of Interleukin-6 production in rheumatoid arthritis synovial fibroblasts.* Arthritis Rheumatol. 2015 Oct;67(10):2624-33
128. Barthel C, Wiegand S, Scharl S, **Scharl M**, Frei P, Vavricka SR, Fried M, Sulz MC, Wiegand N, Rogler G, Biedermann L. *Patients' perceptions on the impact of coffee consumption in inflammatory bowel disease: friend or foe?--a patient survey.* Nutr J. 2015 Aug 12;14:78
129. Spalinger MR, Kasper S, Chassard C, Raselli T, Frey-Wagner I, Gottier C, Lang S, Atrott K, Vavricka SR, Mair F, Becher B, Lacroix C, Fried M, Rogler G, **Scharl M**. *PTPN2 controls differentiation of CD4<sup>+</sup> T cells and limits intestinal inflammation and intestinal dysbiosis.* Mucosal Immunol. 2015 Jul;8(4):918-29
130. de Vallière C, Wang Y, Eloranta JJ, Vidal S, Clay I, Spalinger MR, Tcymbarevich I, Terhalle A, Ludwig MG, Suply T, Fried M, Kullak-Ublick GA, Frey-Wagner I, **Scharl M**, Seuwen K, Wagner CA, Rogler G. *G Protein-coupled pH-sensing Receptor OGR1 Is a Regulator of Intestinal Inflammation.* Inflamm Bowel Dis. 2015 Jun;21(6):1269-81
131. **Scharl M**, Huber N, Lang S, Fürst A, Jehle E, Rogler G. *Hallmarks of epithelial to mesenchymal transition are detectable in Crohn's disease associated intestinal fibrosis.* Clin Transl Med. 2015 Feb 7;4:1
132. Kasper SH, Spalinger MR, Raselli T, **Scharl M**. *A cell type-specific role of protein tyrosine phosphatase non-receptor type 2 in regulating ER stress signalling.*



Digestion. 2015;91(3):248-56.

133. Roth S, Spalinger MR, Müller I, Lang S, Rogler G, **Scharl M**.  
*Bilberry-derived anthocyanins prevent IFN- $\gamma$ -induced pro-inflammatory signalling and cytokine secretion in human THP-1 monocytic cells.*  
Digestion. 2014;90(3):179-89
134. Biedermann L, Brülisauer K, Zeitz J, Frei P, **Scharl M**, Vavricka SR, Fried M, Loessner MJ, Rogler G, Schuppler M.  
*Smoking cessation alters intestinal microbiota: insights from quantitative investigations on human fecal samples using FISH.*  
Inflamm Bowel Dis. 2014 Sep;20(9):1496-501
135. Maillard MH, Bortolotti M, Vader JP, Mottet C, Schoepfer A, Gonvers JJ, Burnand B, Froehlich F, Michetti P9, Pittet V; **Swiss IBD Cohort Study Group**.  
*Appropriateness and long-term discontinuation rate of biological therapies in ulcerative colitis.*  
J Crohns Colitis. 2014 Aug;8(8):825-34
136. Gutiérrez A, **Scharl M**, Sempere L, Holler E, Zapater P, Almenta I, González-Navajas JM, Such J, Wiest R, Rogler G, Francés R.  
*Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease.*  
Gut. 2014 Feb;63(2):272-80
137. Barthel C, Biedermann L, Frei P, Vavricka SR, Kündig T, Fried M, Rogler G, **Scharl M**.  
*Induction or exacerbation of psoriasis in patients with Crohn's disease under treatment with anti-TNF antibodies.*  
Digestion. 2014;89(3):209-15
138. Becker HM, Apladas A, **Scharl M**, Fried M, Rogler G.  
*Probiotic Escherichia coli Nissle 1917 and commensal E. coli K12 differentially affect the inflammasome in intestinal epithelial cells.*  
Digestion. 2014;89(2):110-8
139. Vavricka SR, Manser CN, Hediger S, Vögelin M, **Scharl M**, Biedermann L, Rogler S, Seibold F, Sanderink R, Attin T, Schoepfer A, Fried M, Rogler G, Frei P.  
*Periodontitis and gingivitis in inflammatory bowel disease: a case-control study.*  
Inflamm Bowel Dis. 2013 Dec;19(13):2768-77
140. Frei SM, Pesch T, Lang S, Weber A, Jehle E, Vavricka SR, Fried M, Rogler G, **Scharl M**.  
*A role for tumor necrosis factor and bacterial antigens in the pathogenesis of Crohn's disease-associated fistulae.*  
Inflamm Bowel Dis. 2013 Dec;19(13):2878-87.
141. Frei SM, Hemsley C, Pesch T, Lang S, Weber A, Jehle E, Rühl A, Fried M, Rogler G, **Scharl M**.  
*The role for dickkopf-homolog-1 in the pathogenesis of Crohn's disease-associated fistulae.*  
PLoS One. 2013 Nov 8;8(11):e78882

- 
142. Morón B, Spalinger M, Kasper S, Atrott K, Frey-Wagner I, Fried M, McCole DF, Rogler G, **Scharl M**. *Activation of protein tyrosine phosphatase non-receptor type 2 by spermidine exerts anti-inflammatory effects in human THP-1 monocytes and in a mouse model of acute colitis*. PLoS One. 2013 Sep 9;8(9):e73703.
143. Spalinger MR, Lang S, Vavricka SR, Fried M, Rogler G, **Scharl M**. *Protein tyrosine phosphatase non-receptor type 22 modulates NOD2-induced cytokine release and autophagy*. PLoS One. 2013 Aug 26;8(8):e72384
144. Pittet V, Rogler G, Michetti P, Fournier N, Vader JP, Schoepfer A, Mottet C, Burnand B, Froehlich F; **Swiss Inflammatory Bowel Disease Cohort Study Group**. *Penetrating or stricturing diseases are the major determinants of time to first and repeat resection surgery in Crohn's disease*. Digestion. 2013;87(3):212-21
145. Wojtal KA, Wolfram L, Frey-Wagner I, Lang S, **Scharl M**, Vavricka SR, Rogler G. *The effects of vitamin A on cells of innate immunity in vitro*. Toxicol In Vitro. 2013 Aug;27(5):1525-32
146. Biedermann L, Zeitz J, Mwinyi J, Sutter-Minder E, Rehman A, Ott SJ, Steurer-Stey C, Frei A, Frei P, **Scharl M**, Loessner MJ, Vavricka SR, Fried M, Schreiber S, Schuppler M, Rogler G. *Smoking cessation induces profound changes in the composition of the intestinal microbiota in humans*. PLoS One. 2013;8(3)
147. Kelly OB, Mroz MS, Ward JB, Colliva C, **Scharl M**, Pellicciari R, Gilmer JF, Fallon PG, Hofmann AF, Roda A, Murray FE, Keely SJ. *Ursodeoxycholic acid attenuates colonic epithelial secretory function*. J Physiol. 2013 May 1;591(9):2307-18
148. Biedermann L, Mwinyi J, **Scharl M**, Frei P, Zeitz J, Kullak-Ublick GA, Vavricka SR, Fried M, Weber A, Humpf HU, Peschke S, Jetter A, Krammer G, Rogler G. *Bilberry ingestion improves disease activity in mild to moderate ulcerative colitis - an open pilot study*. J Crohns Colitis. 2013 May;7(4):271-9.
149. Spalinger MR, Lang S, Weber A, Frei P, Fried M, Rogler G, **Scharl M**. *Loss of protein tyrosine phosphatase nonreceptor type 22 regulates interferon- $\gamma$ -induced signaling in human monocytes*. Gastroenterology. 2013 May;144(5):978-988.e10
150. **Scharl M**, Frei S, Pesch T, Kellermeier S, Arikkat J, Frei P, Fried M, Weber A, Jehle E, Rühl A, Rogler G. *Interleukin-13 and transforming growth factor  $\beta$  synergise in the pathogenesis of human intestinal fistulae*. Gut. 2013 Jan;62(1):63-72
151. Wojtal KA, Rogler G, **Scharl M**, Biedermann L, Frei P, Fried M, Weber A, Eloranta JJ, Kullak-Ublick GA, Vavricka SR. *Fc gamma receptor CD64 modulates the inhibitory activity of infliximab*. PLoS One. 2012;7(8):e43361

152. Vavricka SR, Bentele N, **Scharl M**, Rogler G, Zeitz J, Frei P, Straumann A, Binek J, Schoepfer AM, Fried M; Swiss IBDnet and Swiss IBD Cohort Study Group.  
*Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL).*  
Inflamm Bowel Dis. 2012 Aug;18(8):1523-30.
153. **Scharl M**, Wojtal KA, Becker HM, Fischbeck A, Frei P, Arikkat J, Pesch T, Kellermeier S, Boone DL, Weber A, Loessner MJ, Vavricka SR, Fried M, McCole DF, Rogler G.  
*Protein tyrosine phosphatase nonreceptor type 2 regulates autophagosome formation in human intestinal cells.*  
Inflamm Bowel Dis. 2012 Jul;18(7):1287-302
154. **Scharl M**, Mwinyi J, Fischbeck A, Leucht K, Eloranta JJ, Arikkat J, Pesch T, Kellermeier S, Mair A, Kullak-Ublick GA, Truninger K, Noreen F, Regula J, Gaj P, Pittet V, Mueller C, Hofmann C, Fried M, McCole DF, Rogler G.  
*Crohn's disease-associated polymorphism within the PTPN2 gene affects muramyl-dipeptide-induced cytokine secretion and autophagy.*  
Inflamm Bowel Dis. 2012 May;18(5):900-12
155. **Scharl M**, Weber A, Fürst A, Farkas S, Jehle E, Pesch T, Kellermeier S, Fried M, Rogler G.  
*Potential role for SNAIL family transcription factors in the etiology of Crohn's disease-associated fistulae.*  
Inflamm Bowel Dis. 2011 Sep;17(9):1907-16
156. Vavricka SR, Schoepfer AM, Banský G, Binek J, Felley C, Geyer M, Manz M, Rogler G, de Saussure P, Sauter B, **Scharl M**, Seibold F, Straumann A, Michetti P; Swiss IBDnet.  
*Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey.*  
Inflamm Bowel Dis. 2011 Jul;17(7):1530-9
157. **Scharl M**, Leucht K, Frey-Wagner I, Zeitz J, Hausmann M, Fischbeck A, Liebisch G, Kellermeier S, Pesch T, Arikkat J, Schmitz G, Fried M, Yildiz Y, Rogler G.  
*Knock-out of  $\beta$ -glucosidase 2 has no influence on dextran sulfate sodium-induced colitis.*  
Digestion. 2011;84(2):156-67
158. **Scharl M**, McCole DF, Weber A, Vavricka SR, Frei P, Kellermeier S, Pesch T, Fried M, Rogler G.  
*Protein tyrosine phosphatase N2 regulates TNF $\alpha$ -induced signalling and cytokine secretion in human intestinal epithelial cells.*  
Gut. 2011 Feb;60(2):189-97
159. Meier JK, **Scharl M**, Miller SN, Brenmoehl J, Hausmann M, Kellermeier S, Schölmerich J, Rogler G.  
*Specific differences in migratory function of myofibroblasts isolated from Crohn's disease fistulae and strictures.*  
Inflamm Bowel Dis. 2011 Jan;17(1):202-12
160. **Scharl M**, Hruz P, McCole DF.  
*Protein tyrosine phosphatase non-receptor Type 2 regulates IFN- $\gamma$ -induced cytokine signaling in THP-1 monocytes.*  
Inflamm Bowel Dis. 2010 Dec;16(12):2055-64
161. **Scharl M**, Geisel S, Vavricka SR, Rogler G.

*Dying in yoghurt: the number of living bacteria in probiotic yoghurt decreases under exposure to room temperature.*  
Digestion. 2011;83(1-2):13-7

162. **Scharl M**, Rudenko I, McCole DF.  
*Loss of protein tyrosine phosphatase N2 potentiates epidermal growth factor suppression of intestinal epithelial chloride secretion.*  
Am J Physiol Gastrointest Liver Physiol. 2010 Oct;299(4):G935-45
163. Hoda MR, **Scharl M**, Keely SJ, McCole DF, Barrett KE.  
*Apical leptin induces chloride secretion by intestinal epithelial cells and in a rat model of acute chemotherapy-induced colitis.*  
Am J Physiol Gastrointest Liver Physiol. 2010 May;298(5):G714-21
164. **Scharl M**, Paul G, Weber A, Jung BC, Docherty MJ, Hausmann M, Rogler G, Barrett KE, McCole DF.  
*Protection of epithelial barrier function by the Crohn's disease associated gene protein tyrosine phosphatase n2.*  
Gastroenterology. 2009 Dec;137(6):2030-2040.e5
165. **Scharl M**, Paul G, Barrett KE, McCole DF.  
*AMP-activated protein kinase mediates the interferon-gamma-induced decrease in intestinal epithelial barrier function.*  
J Biol Chem. 2009 Oct 9;284(41):27952-63
166. Keating N, Mroz MS, **Scharl MM**, Marsh C, Ferguson G, Hofmann AF, Keely SJ.  
*Physiological concentrations of bile acids down-regulate agonist induced secretion in colonic epithelial cells.*  
J Cell Mol Med. 2009 Aug;13(8B):2293-303
167. Keely SJ, **Scharl MM**, Bertelsen LS, Hagey LR, Barrett KE, Hofmann AF.  
*Bile acid-induced secretion in polarized monolayers of T84 colonic epithelial cells: Structure-activity relationships.*  
Am J Physiol Gastrointest Liver Physiol. 2007 Jan;292(1):G290-7.
168. Langmann T, Moehle C, Mauerer R, **Scharl M**, Liebisch G, Zahn A, Stremmel W, Schmitz G.  
*Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes.*  
Gastroenterology. 2004 Jul;127(1):26-40.

## 2. Übersichtsartikel

1. Häfliger J, Morsy Y, **Scharl M**, Wawrzyniak M.  
*From Patient Material to New Discoveries: a Methodological Review and Guide for Intestinal Stem Cell Researchers.*  
Stem Cell Rev Rep. 2022 Apr;18(4):1309-1321. doi: 10.1007/s12015-021-10307-7. Epub 2022 Jan 17.
2. Caparrós E, Wiest R, **Scharl M**, Rogler G, Gutiérrez Casbas A, Yilmaz B, Wawrzyniak M, Francés R.  
*Dysbiotic microbiota interactions in Crohn's disease.*  
Gut Microbes. 2021 Jan-Dec;13(1):1949096. doi: 10.1080/19490976.2021.1949096
3. Manz SM, Losa M, Fritsch R, **Scharl M**.  
*Efficacy and side effects of immune checkpoint inhibitors in the treatment of colorectal cancer.*  
Therap Adv Gastroenterol. 2021 Apr 15;14:17562848211002018. doi: 10.1177/17562848211002018.
4. Dart RJ, Ellul P, **Scharl M**, Lamb CA; Scientific Workshop Steering Committee  
*Results of the Seventh Scientific Workshop of ECCO: Precision medicine in IBD - Challenges and future directions.*  
J Crohns Colitis. 2021 Sep 25;15(9):1407-1409. doi: 10.1093/ecco-jcc/jjab049
5. Fiocchi C, Dragoni G, Iliopoulos D, Katsanos K, Hernandez Ramirez V, Suzuki K, Verstockt B, Torres J, **Scharl M**.  
*Results of the Seventh Scientific Workshop of ECCO: Precision medicine in IBD - what, why, and how.*  
J Crohns Colitis. 2021 Sep 25;15(9):1410-1430. doi: 10.1093/ecco-jcc/jjab051
6. Verstockt B, Noor NM, Marigorta UM, Pavlidis P, Deepak P, Ungaro RC, Fiocchi C, Torres J, **Scharl M**.  
*Results of the Seventh Scientific Workshop of ECCO: Precision medicine in IBD - disease outcome and response to therapy.*  
J Crohns Colitis . 2021 Sep 25;15(9):1431-1442. doi: 10.1093/ecco-jcc/jjab050
7. Torres J, Halfvarson J, Rodríguez-Lago I, Hedin CRH, Jess T, Dubinsky M, Croitoru K, Colombel JF, Verstockt B, Fiocchi C, **Scharl M**.  
*Results of the Seventh Scientific Workshop of ECCO: Precision medicine in IBD- prediction and prevention of inflammatory bowel disease.*  
J Crohns Colitis. 2021 Sep 25;15(9):1443-1454. doi: 10.1093/ecco-jcc/jjab048
8. Rogler G, **Scharl M**, Spalinger M, Yilmaz B, Zaugg M, Hersberger M, Schreiner P, Biedermann L, Herfarth H.  
*Diet and Inflammatory Bowel Disease - What Quality Standards Should be Applied in Clinical and Laboratory Studies?*  
Mol Nutr Food Res. 2021 Mar;65(5):e2000514. doi: 10.1002/mnfr.202000514.
9. Lucchinetti E, Lou PH, Wawrzyniak P, Wawrzyniak M, **Scharl M**, Holtzhauer GA, Krämer SD, Hersberger M, Rogler G, Zaugg M.  
*Novel Strategies to Prevent Total Parenteral Nutrition-Induced Gut and Liver Inflammation, and Adverse Metabolic Outcomes.*  
Mol Nutr Food Res. 2021 Mar;65(5):e1901270. doi: 10.1002/mnfr.201901270

10. Greuter T, Vavricka S, König AO, Beaugerie L, **Scharl M**; Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology.  
*Malignancies in Inflammatory Bowel Disease.*  
*Digestion.* 2020;101 Suppl 1:136-145. doi: 10.1159/000509544.
11. Spalinger MR, Schwarzfischer M, **Scharl M**.  
*The Role of Protein Tyrosine Phosphatases in Inflammasome Activation.*  
*Int J Mol Sci.* 2020 Jul 31;21(15):5481. doi: 10.3390/ijms21155481.
12. Ploner M, Gardetto A, Ploner F, **Scharl M**, Shoap S, Bäcker HC.  
*Foreign rectal body - Systematic review and meta-analysis.*  
*Acta Gastroenterol Belg.* 2020 Jan-Mar;83(1):61-65.
13. Barnhoorn MC, Hakuno SK, Bruckner RS, Rogler G, Hawinkels LJAC, **Scharl M**.  
*Stromal Cells in the Pathogenesis of Inflammatory Bowel Disease.*  
*J Crohns Colitis.* 2020 Mar 11. pii: jjaa009. doi: 10.1093/ecco-jcc/jjaa009.
14. Montalban-Arques A, **Scharl M**.  
*Intestinal microbiota and colorectal carcinoma: Implications for pathogenesis, diagnosis, and therapy.*  
*EBioMedicine.* 2019 Oct;48:648-655. doi: 10.1016/j.ebiom.2019.09.050.
15. **Scharl M**.  
*Perianal fistulas in CED: from mouse model to clinic*  
*Ther Umsch.* 2019 Jan;75(5):287-294
16. Wawrzyniak M, **Scharl M**.  
*Genetics and epigenetics of inflammatory bowel disease*  
*Swiss Med Wkly.* 2018 Sep 23;148:w14671.
17. Butter M, Weiler S, Biedermann L, **Scharl M**, Rogler G, Bischoff-Ferrari HA, Misselwitz B.  
*Clinical manifestations, pathophysiology, treatment and outcome of inflammatory bowel diseases in older people.*  
*Maturitas.* 2018 Apr;110:71-78.
18. Rogler G, Biedermann L, **Scharl M**.  
*New insights into the pathophysiology of inflammatory bowel disease: microbiota, epigenetics and common signalling pathways.*  
*Swiss Med Wkly.* 2018 Mar 22;148:w14599.
19. **Scharl M**, Rogler G, Biedermann L.  
*Fistulizing Crohn's Disease.*  
*Clin Transl Gastroenterol.* 2017 Jul 13;8(7):e106
20. **Scharl M**, Rogler G, Biedermann L  
*Anthocyanins, blueberries and curcuma: Effective therapeutic agents for bowel inflammations?*

Schweizerische Zeitschrift für Ganzheitsmedizin, Volume 29, Issue 3, 1 June 2017, Pages 137-140

21. Rogler G, Biedermann L, **Scharl M**.  
*Anti-Cytokine Strategies beyond Anti-Tumour Necrosis Factor- $\alpha$  Therapy: Pathophysiology and Clinical Implications.*  
Dig Dis. 2017;35(1-2):5-12.
22. **Scharl M**, Bruckner RS, Rogler G.  
*The two sides of the coin: Similarities and differences in the pathomechanisms of fistulas and stricture formations in irritable bowel disease.*  
United European Gastroenterol J. 2016 Aug;4(4):506-14.
23. Siegmund B, Feakins RM, Barmias G, Ludvig JC, Teixeira FV, Rogler G, **Scharl M**.  
*Results of the Fifth Scientific Workshop of the ECCO (II): Pathophysiology of Perianal Fistulizing Disease.*  
J Crohns Colitis. 2016 Apr;10(4):377-86
24. Spalinger MR, **Scharl M**.  
*The role for protein tyrosine phosphatase non-receptor type 22 in regulating intestinal homeostasis.*  
United European Gastroenterol J. 2016 Jun;4(3):325-32.
25. Spalinger MR, McCole DF, Rogler G, **Scharl M**.  
*Protein tyrosine phosphatase non-receptor type 2 and inflammatory bowel disease.*  
World J Gastroenterol. 2016 Jan 21;22(3):1034-44.
26. Vavricka SR, Schoepfer A, **Scharl M**, Lakatos PL, Navarini A, Rogler G.  
*Extraintestinal Manifestations of Inflammatory Bowel Disease.*  
Inflamm Bowel Dis. 2015 Aug;21(8):1982-92
27. Spalinger MR, McCole DF, Rogler G, **Scharl M**.  
*Role of protein tyrosine phosphatases in regulating the immune system: implications for chronic intestinal inflammation.*  
Inflamm Bowel Dis. 2015 Mar;21(3):645-55
28. **Scharl M**, Schaer D, Vallelian F.  
*[CME. Biologics in vasculitis].*  
Praxis (Bern 1994). 2015 Jan 2;104(1):7-16; quiz 15. Erratum in: Praxis (Bern 1994). 2015 Jan 28;104(3):116.
29. Gutermann IK, Niggemeier V, Zimmerli LU, Holzer BM, Battegay E, **Scharl M**.  
*Gastrointestinal bleeding and anticoagulant or antiplatelet drugs: systematic search for clinical practice guidelines.*  
Medicine (Baltimore). 2015 Jan;94(1):e377
30. Vavricka SR, **Scharl M**, Gubler M, Rogler G.  
*Biologics for extraintestinal manifestations of IBD.*  
Curr Drug Targets. 2014;15(11):1064-73

31. **Scharl M**, Rogler G.  
*Pathophysiology of fistula formation in Crohn's disease.*  
World J Gastrointest Pathophysiol. 2014 Aug 15;5(3):205-12
32. Vavricka SR, Schoepfer AM, **Scharl M**, Rogler G.  
*Steroid use in Crohn's disease.*  
Drugs. 2014 Mar;74(3):313-24
33. **Scharl M**, Barthel C, Rogler G.  
*[Therapy of complicated Crohn's disease].*  
Praxis (Bern 1994). 2014 Mar 12;103(6):323-7
34. **Scharl M**.  
*[Therapy of chronic inflammatory bowel diseases: what comes next?].*  
Praxis (Bern 1994). 2014 Feb 12;103(4):185-6
35. **Scharl M**, Biedermann L, Rogler G.  
*Colitis-associated colorectal carcinoma: epidemiology, pathogenesis and early diagnosis].*  
Praxis (Bern 1994). 2014 Jan 29;103(3):149-54
36. Spalinger MR, Rogler G, **Scharl M**.  
*Crohn's disease: loss of tolerance or a disorder of autophagy?*  
Dig Dis. 2014;32(4):370-7
37. **Scharl M**, Vavricka SR, Rogler G.  
*Review: new anti-cytokines for IBD: what is in the pipeline?*  
Curr Drug Targets. 2013 Nov;14(12):1405-20
38. **Scharl M**, Rogler G.  
*Inflammatory bowel disease: dysfunction of autophagy?*  
Dig Dis. 2012;30 Suppl 3:12-9
39. **Scharl M**, Rogler G.  
*Inflammatory bowel disease pathogenesis: what is new?*  
Curr Opin Gastroenterol. 2012 Jul;28(4):301-9
40. **Scharl M**, Rogler G.  
*The role for protein tyrosine phosphatase nonreceptor type 2 in regulating autophagosome formation.*  
Ann N Y Acad Sci. 2012 Jun;1257:93-102
41. **Scharl M**, Rogler G.  
*Microbial sensing by the intestinal epithelium in the pathogenesis of inflammatory bowel disease.*  
Int J Inflam. 2010 Jun 29;2010:671258



42. **Scharl M**, Rogler G.  
[*Biologicals in gastroenterology: TNF-blockers*].  
Dtsch Med Wochenschr. 2010 Nov;135(45):2243-52

### 3. Andere Publikationen

#### Buchbeiträge

1. **Scharl M**.  
Rogler G, Herfarth H, Hibi T, Nielsen OH (eds):  
*Physiological Role of TNF in Mucosal Immunology: Regulation of T-Cell Function*  
Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease.  
Front Gastrointest Res. Basel, Karger, 2015, vol 34, pp 27-34
2. **Scharl M**.  
Rogler G, Herfarth H, Hibi T, Nielsen OH (eds):  
*Pathophysiological Role of TNF in Inflammatory Bowel Disease: TNF and Its Effect on Innate Immune Defense*  
Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease.  
Front Gastrointest Res. Basel, Karger, 2015, vol 34, pp 49-55
3. Vavricka SR, **Scharl M**, Rogler G  
Rogler G, Herfarth H, Hibi T, Nielsen OH (eds):  
*Pathophysiological Role of TNF in Inflammatory Bowel Disease: Anti-TNF therapy before surgery*  
Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease.  
Front Gastrointest Res. Basel, Karger, 2015, vol 34, pp 219-23

#### Guidelines

1. Gordon H, Biancone L, Fiorino G, Katsanos KH, Kopylov U, Sulais EA, Axelrad JE, Balendran K, Burisch J, de Ridder L, Derikx L, Ellul P, Greuter T, Iacucci M, Di Jiang C, Kapizioni C, Karmiris K, Kirchgesner J, Laharie D, Lobatón Ortega T, Molnár T, Noor NM, Rao R, Saibeni S, **Scharl M**, Vavricka SR, Raine T.  
*ECCO Guidelines on Inflammatory Bowel Disease and Malignancies*.  
J Crohns Colitis. 2022 Dec 18;jjac187. doi: 10.1093/ecco-jcc/jjac187. Online ahead of print
2. Torres J, Chaparro M, Julsgaard M, Katsanos K, Zelinkova Z, Agrawal M, Ardizzone S, Campmans-Kuijpers M, Dragoni G, Ferrante M, Fiorino G, Flanagan E, Frias Gomes C, Hart A, Hedin CR, Juillerat P, Mulders A, Myrelid P, O'Toole A, Rivière P, **Scharl M**, Selinger CP, Sonnenberg E, Toruner M, Wieringa J, Van der Woude CJ.  
*European Crohn's and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation*.  
J Crohns Colitis. 2022 Aug 25;jjac115. doi: 10.1093/ecco-jcc/jjac115. Online ahead of print
3. Klionsky DJ et al.  
*Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)*.  
Autophagy. 2021 Jan;17(1):1-382. doi: 10.1080/15548627.2020.1797280.

4. Magro F, Doherty G, Peyrin-Biroulet L, Svrcek M, Borralho P, Walsh A, Carneiro F, Rosini F, de Hertogh G, Biedermann L, Pouillon L, **Scharl M**, Tripathi M, Danese S, Villanacci V, Feakins R. *ECCO Position Paper: Harmonisation of the approach to Ulcerative Colitis Histopathology*. J Crohns Colitis. 2020 Nov 7;14(11):1503-1511. doi: 10.1093/ecco-jcc/jjaa110
5. Klionsky DJ et al. *Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)*. Autophagy. 2016;12(1):1-222
6. Klionsky DJ et al. *Guidelines for the use and interpretation of assays for monitoring autophagy*. Autophagy. 2012 Apr;8(4):445-544.

### Case reports

1. Morell B, Buehler PK, Bader PR, Lang S, **Scharl M**, Gubler C, Murray FR. *Efficient treatment of esophageal nutrition bezoars: dissolution outmatches removal-the Zurich approach*. Clin J Gastroenterol. 2021 Dec;14(6):1602-1606. doi: 10.1007/s12328-021-01516-1.
2. Kochar B, Herfarth N, Mamie C, Navarini AA, **Scharl M**, Herfarth HH. *Tofacitinib for the Treatment of Pyoderma Gangrenosum*. Clin Gastroenterol Hepatol. 2019 Apr;17(5):991-993.
3. Russi L, **Scharl M**, Rogler G, Biedermann L. *The Efficacy and Safety of Golimumab as Third- or Fourth-Line Anti-TNF Therapy in Patients with Refractory Crohn's Disease: A Case Series*. Inflamm Intest Dis. 2017 Nov;2(2):131-138.
4. **Scharl M**, Biedermann L. *A Symptomatic Coffee Bean: Acute Sigmoid Volvulus*. Case Rep Gastroenterol. 2017 May 22;11(2):348-351.
5. Misselwitz B, Epprecht J, Mertens J, Biedermann L, **Scharl M**, Haralambieva E, Lutterotti A, Weber KP, Müllhaupt B, Chaloupka K. *Orbital Pseudotumor as a Rare Extrahepatic Manifestation of Hepatitis C Infection*. Case Rep Gastroenterol. 2016 May 19;10(1):108-14
6. Vavricka SR, Greuter T, **Scharl M**, Mantzaris G, Shitrit AB, Filip R, Karmiris K, Thoeringer CK, Boldys H, Wewer AV, Yanai H, Flores C, Schmidt C, Kariv R, Rogler G, Rahier JF; ECCO CONFER investigators. *Cogan's Syndrome in Patients With Inflammatory Bowel Disease--A Case Series*. J Crohns Colitis. 2015 Oct;9(10):886-90
7. **Scharl M**, Stanek N, Kröger A, Bauerfeind P, Gubler C. *Successful treatment of a proximal esophageal rupture with a luminal sponge*. Endoscopy. 2015;47 Suppl 1 UCTN:E293-4

8. **Scharl M**, Bode B, Rushing E, Knuth A, Rordorf T.  
*Uncommon case of brain metastasis in a patient with a history of heavy smoking.*  
Curr Oncol. 2014 Oct;21(5):e728-31
9. Barthel C, Spalinger MR, Brunner J, Lang S, Fried M, Rogler G, **Scharl M**.  
*A distinct pattern of disease-associated single nucleotide polymorphisms in IBD risk genes in a family with Crohn's disease.*  
Eur J Gastroenterol Hepatol. 2014 Jul;26(7):803-6.
10. **Scharl M**, Frei P, Frei SM, Biedermann L, Weber A, Rogler G.  
*Epithelial-to-mesenchymal transition in a fistula-associated anal adenocarcinoma in a patient with long-standing Crohn's disease.*  
Eur J Gastroenterol Hepatol. 2014 Jan;26(1):114-8
11. **Scharl M**, Frei P, Fried M, Rogler G, Vavricka SR.  
*Association between Cogan's syndrome and inflammatory bowel disease: a case series.*  
J Crohns Colitis. 2011 Feb;5(1):64-8.

#### Protocols

1. Bieri U, **Scharl M**, Sigg S, Szczerba BM, Morsy Y, Rüschoff JH, Schraml PH, Krauthammer M, Hefermehl LJ, Eberli D, Poyet C.  
*Prospective observational study of the role of the microbiome in BCG responsiveness prediction (SILENT-EMPIRE): a study protocol.*  
BMJ Open. 2022 Apr 18;12(4):e061421. doi: 10.1136/bmjopen-2022-061421

#### Comments

1. Response to Al Sulais et al.  
Greuter T, Vavricka SR, Scharl M.  
Am J Gastroenterol. 2019 Aug;114(8):1346-1347. doi: 10.14309/ajg.0000000000000318.

#### Errata

1. Kiessling MK, Curioni-Fontecedro A, Samaras P, Lang S, **Scharl M**, Aguzzi A, Oldridge DA, Maris JM, Rogler G.  
*Correction: Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma.*  
PLoS One. 2017 Jan 20;12(1):e0170851
2. **Scharl M**, Bruckner RS, Rogler G.  
*The two sides of the coin: Similarities and differences in the pathomechanisms of fistulas and stricture formations in irritable bowel disease.*  
United European Gastroenterol J. 2016 Dec;4(6):816.
3. Spalinger MR, Kasper S, Gottier C, Lang S, Atrott K, Vavricka SR, Scharl S, Raselli T, Frey-Wagner I, Gutte PM, Grütter MG, Beer HD, Contassot E, Chan AC, Dai X, Rawlings DJ, Mair F, Becher B, Falk W, Fried M, Rogler G, **Scharl M**.

*NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22.*  
J Clin Invest. 2016 Nov 1;126(11):4388.

4. Siegmund B, Feakins RM, Barmias G, Ludvig JC, Teixeira FV, Rogler G, **Scharl M**.  
*Results of the Fifth Scientific Workshop of the ECCO (II): Pathophysiology of Perianal Fistulizing Disease.*  
J Crohns Colitis. 2016 Jul;10(7):870.
  
5. Klionsky DJ et al.  
*Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).*  
Autophagy. 2016;12(2):443. Selliez, Iban [corrected to Seilliez, Iban].
  
6. **Scharl M**, Schaer D, Vallelian F.  
*[CME. Biologics in vasculitis].*  
Praxis (Bern 1994). 2015 Jan 28;104(3):116.